Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case
- 18 February 2025
- journal article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 38 (6) , 354-360
Abstract
BACKGROUND: Primary aldosteronism (PA) is the main cause of secondary arterial hypertension. In this study, we present the medical treatment of Hispanic patients with PA followed for up to 5 years, highlighting the complete cure with pharmacological treatment in one of our patients. METHODS: We studied 32 PA patients, followed every 6 months after starting MRA. A clinical response was the normalization of blood pressure (BP) in the absence of other antihypertensive drugs. The biochemical response was considered with normalization of potassium and renin. Responses to treatment were compared using the defined daily dose (DDD). The effect of MRA was evaluated in vitro. The HAC15 cells were cultured and stimulated with aldosterone and spironolactone for 24–72 h, and the apoptotic cell death was measured. RESULTS: At 12 months posttreatment with MRA, 68% of the patients had a total clinical response, and 67% had a total biochemical response. Response to MRA treatment reduced DDD by an average of 74%. Additionally, we observed one PA patient treated with spironolactone after 3 years, he presented a pharmacological cure with normalization of aldosterone and renin without treatment with spironolactone. The in vitro study shows that spironolactone increased early apoptosis by 60% and late apoptosis by 50%. CONCLUSIONS: These results suggest the importance of timely diagnosis of PA and specific treatment with MRA, especially in patients with a poor response to treatment. Moreover, remission of PA may occur in some patients after spironolactone treatment due to its suggestive role as an apoptotic agent.Keywords
All Related Versions
Funding Information
- ANID-CONICYT FONDECYT (1212006, 1190419 and 11251675)
This publication has 40 references indexed in Scilit:
- Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohortThe Lancet Diabetes & Endocrinology, 2025
- Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage responseOncogene, 2019
- Contrasting Effects of Eplerenone and Spironolactone on Adrenal Cell SteroidogenesisHormone and Metabolic Research, 2008
- Spironolactone induces apoptosis and inhibits NF-κB independent of the mineralocorticoid receptorApoptosis, 2006
- Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppressionApoptosis, 2006
- Idiopathic primary hyperaldosteronism: Normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoateJournal of Endocrinological Investigation, 2005
- Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-α and interferon-γ, and has potential in the treatment of arthritisClinical and Experimental Immunology, 2003
- Mechanism of action of spironolactone on cortisol production by guinea pig adrenocortical cellsMolecular and Cellular Endocrinology, 1991
- Role of the steroid 17 alpha-hydroxylase in spironolactone-mediated destruction of adrenal cytochrome P-450.Molecular Pharmacology, 1991
- Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7alpha-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450.Journal of Biological Chemistry, 1979